Eli Lilly: The Worst May Be Already Over (Earnings Preview)

Eli Lilly (LLY) is set to report Q2 2025 earnings on August 7, with consensus estimates at $14.4 billion in revenue and $5.56 EPS, representing 30-42% year-over-year growth. Analysts anticipate continued volume-driven expansion and above-industry-average growth through 2026, despite a Q1 EPS miss attributed to IPR&D charges. While competitive headwinds and a high absolute valuation are noted risks, the company's robust pipeline and reaffirmed full-year guidance underpin a maintained "Buy" rating and expectations for significant share price appreciation.

Analysis

Eli Lilly is approaching its Q2 2025 earnings release on August 7 with high market expectations, as consensus estimates project revenue of $14.4 billion and EPS of $5.56, implying significant year-over-year growth between 30% and 42%. This anticipated growth is predicated on continued volume expansion, which is also expected to offset potential price erosion. While the company's Q1 results demonstrated robust 45% revenue growth, a minor EPS miss due to IPR&D charges highlights sensitivity to non-operational expenses, though management's reaffirmation of full-year guidance signals underlying confidence. The primary risks to the outlook include a high absolute valuation, competitive headwinds from peers like Novo Nordisk, and the potential for volume growth to decelerate. However, the long-term thesis is supported by a strong late-stage pipeline and anticipated regulatory submissions, which are positioned to extend the company's growth trajectory beyond its current leadership in the GLP-1 market.

Key Decisions for Investors

• Investors should closely monitor the upcoming Q2 earnings for confirmation of strong volume growth, as this is the key variable expected to offset price pressures and justify lofty consensus forecasts.
• Given the stock's high absolute valuation, any deviation from the guided 30-42% YoY growth or a downward revision to full-year guidance could trigger a significant price correction.
• Beyond the immediate earnings, focus should be on management's commentary regarding the late-stage pipeline and regulatory timelines, as these are crucial for de-risking the long-term growth outlook.
• Pay close attention to competitive dynamics, particularly any commentary on volume trends from peer Novo Nordisk, as this could serve as a leading indicator for potential market saturation or share shifts.